Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives.

Structure-function relationships for the inhibition of human cytochrome P450s (P450s) 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives were studied. Thirty-two of the 33 flavonoids tested produced reverse type I binding spectra with P450 1B1, and the potencies of binding were correlated with the abilities to inhibit 7-ethoxyresorufin O-deethylation activity. The presence of a hydroxyl group in flavones, for example, 3-, 5-, and 7-monohydroxy- and 5,7-dihydroxyflavone, decreased the 50% inhibition concentration (IC50) of P450 1B1 from 0.6 μM to 0.09, 0.21, 0.25, and 0.27 μM, respectively, and 3,5,7-trihydroxyflavone (galangin) was the most potent, with an IC50 of 0.003 μM. The introduction of a 4'-methoxy- or 3',4'-dimethoxy group into 5,7-dihydroxyflavone yielded other active inhibitors of P450 1B1 with IC50 values of 0.014 and 0.019 μM, respectively. The above hydroxyl and/or methoxy groups in flavone molecules also increased the inhibition activity with P450 1A1 but not always toward P450 1A2, where 3-, 5-, or 7-hydroxyflavone and 4'-methoxy-5,7-dihydroxyflavone were less inhibitory than flavone itself. P450 2C9 was more inhibited by 7-hydroxy-, 5,7-dihydroxy-, and 3,5,7-trihydroxyflavones than by flavone but was weakly inhibited by 3- and 5-hydroxyflavone. Flavone and several other flavonoids produced type I binding spectra with P450 3A4, but such binding was not always related to the inhibitiory activities toward P450 3A4. These results indicate that there are different mechanisms of inhibition for P450s 1A1, 1A2, 1B1, 2C9, and 3A4 by various flavonoid derivatives and that the number and position of hydroxyl and/or methoxy groups highly influence the inhibitory actions of flavonoids toward these enzymes. Molecular docking studies suggest that there are different mechanisms involved in the interaction of various flavonoids with the active site of P450s, thus causing differences in inhibition of these P450 catalytic activities by flavonoids.

[1]  Ruth Nussinov,et al.  Theoretical Characterization of Substrate Access/Exit Channels in the Human Cytochrome P450 3A4 Enzyme: Involvement of Phenylalanine Residues in the Gating Mechanism , 2009, The journal of physical chemistry. B.

[2]  Hiroshi Yamazaki,et al.  Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: a structure-function relationship study. , 2009, Chemical research in toxicology.

[3]  K. Nishiguchi,et al.  The structure-activity correlation on the inhibitory effects of flavonoids on cytochrome P450 3A activity. , 2009, Biological & pharmaceutical bulletin.

[4]  Ying Wang,et al.  Mechanism of CYP2C9 Inhibition by Flavones and Flavonols , 2009, Drug Metabolism and Disposition.

[5]  H. Yamazaki,et al.  Interaction of polycyclic aromatic hydrocarbons with human cytochrome P450 1B1 in inhibiting catalytic activity. , 2008, Chemical research in toxicology.

[6]  H. Yamazaki,et al.  Effects of enzyme sources on midazolam 1'-hydroxylation activity catalyzed by recombinant cytochrome P450 3A4 in combination with NADPH-cytochrome P450 reductase. , 2008, Drug metabolism letters.

[7]  J. Arct,et al.  Flavonoids as components of biologically active cosmeceuticals. , 2008, Clinics in dermatology.

[8]  H. Yamazaki,et al.  Heterotropic cooperativity in oxidation mediated by cytochrome p450. , 2008, Current drug metabolism.

[9]  Anup A. Kale,et al.  Cancer phytotherapeutics: role for flavonoids at the cellular level , 2008, Phytotherapy research : PTR.

[10]  M. Foroozesh,et al.  Methoxyflavone Inhibitors of Cytochrome P450 , 2008 .

[11]  P. Ruzza,et al.  Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. , 2008, Biochemical pharmacology.

[12]  T. Walle,et al.  Bioavailable Flavonoids: Cytochrome P450-Mediated Metabolism of Methoxyflavones , 2007, Drug Metabolism and Disposition.

[13]  T. Walle Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass? , 2007, Seminars in cancer biology.

[14]  C David Stout,et al.  Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2*♦ , 2007, Journal of Biological Chemistry.

[15]  T. Walle,et al.  Cancer chemopreventive properties of orally bioavailable flavonoids--methylated versus unmethylated flavones. , 2007, Biochemical pharmacology.

[16]  H. Yamazaki,et al.  Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors. , 2007, Chemical research in toxicology.

[17]  T. Sjögren,et al.  Structural basis for ligand promiscuity in cytochrome P450 3A4 , 2006, Proceedings of the National Academy of Sciences.

[18]  T. Shimada,et al.  Recombinant Enzymes Overexpressed in Bacteria Show Broad Catalytic Specificity of Human Cytochrome P450 2W1 and Limited Activity of Human Cytochrome P450 2S1 , 2006, Molecular Pharmacology.

[19]  F Peter Guengerich,et al.  Kinetics and Thermodynamics of Ligand Binding by Cytochrome P450 3A4* , 2006, Journal of Biological Chemistry.

[20]  Gordon C K Roberts,et al.  IN SILICO AND IN VITRO SCREENING FOR INHIBITION OF CYTOCHROME P450 CYP3A4 BY COMEDICATIONS COMMONLY USED BY PATIENTS WITH CANCER , 2006, Drug Metabolism and Disposition.

[21]  Y. Moon,et al.  Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[22]  M. Foroozesh,et al.  Naphthoflavone propargyl ether inhibitors of cytochrome P450 , 2006 .

[23]  T. Shimada,et al.  Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons. , 2006, Chemical research in toxicology.

[24]  Young In Park,et al.  Effects of hydroxyl group numbers on the B-ring of 5,7-dihydroxyflavones on the differential inhibition of human CYP 1A and CYP1B1 enzymes , 2005, Archives of pharmacal research.

[25]  Shuzhong Zhang,et al.  Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. , 2005, Biochemical pharmacology.

[26]  F. Guengerich,et al.  Cytochrome P450 3A4-catalyzed Testosterone 6β-Hydroxylation Stereochemistry, Kinetic Deuterium Isotope Effects, and Rate-limiting Steps* , 2005, Journal of Biological Chemistry.

[27]  W. Tolleson,et al.  Inhibition of extrahepatic human cytochromes P450 1A1 and 1B1 by metabolism of isoflavones found in Trifolium pratense (red clover). , 2004, Journal of agricultural and food chemistry.

[28]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[29]  Eric F. Johnson,et al.  The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.

[30]  M. Hata,et al.  Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. , 2003, Biochemistry.

[31]  T. Shimada,et al.  Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. , 2003, Mutation research.

[32]  E. Offord,et al.  In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[33]  H. Yamazaki,et al.  Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. , 2002, Protein expression and purification.

[34]  Thomas Walle,et al.  Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[35]  M. Stiborová,et al.  Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. , 2002, Chemico-biological interactions.

[36]  M. Burke,et al.  Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. , 2000, Toxicology.

[37]  S. Zhai,et al.  Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[38]  K Chiba,et al.  Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. , 1998, Biochemical pharmacology.

[39]  F. Guengerich,et al.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.

[40]  T. Shimada,et al.  Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. , 1989, Cancer research.

[41]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[42]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[43]  Hideyuki Ito,et al.  Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. , 2010, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[44]  W. Baird,et al.  Urban dust particulate matter alters PAH-induced carcinogenesis by inhibition of CYP1A1 and CYP1B1. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[45]  Tsutomu Shimada,et al.  Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. , 2006, Drug metabolism and pharmacokinetics.

[46]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.